The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats
Abstract
Background Peroxisome proliferator-activated receptor (PPAR)alpha is highly expressed in the heart. PPAR alpha may play a role in cardiac hypertrophy, but effects on cardiac function, inflammation, and fibrosis are unknown. We tested the hypothesis that the PPAR alpha activator fenofibrate prevents myocardial inflammation and fibrosis in angiotensin (Ang) II-infused rats. Methods and results Sprague Dawley rats received Ang II (120 ng/kg/min subcutaneously), fenofibrate (100 mg/kg/d p.o.), or Ang II + fenofibrate. After 7 d, systolic blood pressure (mmHg) was elevated (P < 0.01) in Ang II-infused rats (173 +/- 4) vs. controls (115 +/- 2) and reduced by fenofibrate (137 +/- 5). Electrophoretic mobility shift assay demonstrated that Ang II upregulated cardiac nuclear factor kappa B activity by 50%. Ang II significantly increased cardiac expression of vascular-cell adhesion molecule-1, platelet endothelial cell adhesion molecule, and intercellular adhesion molecule-1. Increases in expression of these inflammatory mediators were normalized by fenofibrate. Ang II-induced expression of transforming growth factor-beta 1, collagen deposition, and macrophage infiltration were partially prevented by fenofibrate. Conclusions The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats. The hypolipidemic drug fenofibrate may be useful in prevention and treatment of myocardial disease associated with hypertension and hyperlipidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diep et al. [101] and Goya et al. [102] reported that FF increases endothelial Nitric Oxide (NO) availability.”
From Fenofibrate and metabolic syndrome (2010) · cites this paper as [101]
Citations
Cites
Sahn, D. J., DeMaria, A. N., KISSLO, J. A., & Weyman, A. E. (1978) · Circulation · doi:10.1161/01.cir.58.6.1072 · Cited by 7,430
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Weber, K. T., & Brilla, C. G. (1991) · Circulation · doi:10.1161/01.cir.83.6.1849 · Cited by 2,035
Molecular Mechanisms of Myocardial Remodeling
Swynghedauw, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.215 · Cited by 1,468
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
Staels, B., Köenig, W., Habib, A., Merval, R., Lebret, M., Pineda‐Torra, I., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,138
Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7473 · Cited by 943
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 1×
“anti-inflammatory activity [15,16].”
Marx, N., Sukhova, G. K., Collins, T., Libby, P., & Plutzky, J. (1999) · Circulation · doi:10.1161/01.cir.99.24.3125 · Cited by 603
Gulick, T., Cresci, S., Caira, T., Moore, D. D., & Kelly, D. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11012 · Cited by 567
Poynter, M. E., & Daynes, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32833 · Cited by 556
Cardiac Actions Of Angiotensin II: Role Of An Intracardiac Renin-Angiotensin System
Baker, K. M., Booz, G. W., & Dostal, D. E. (1992) · Annual Review of Physiology · doi:10.1146/annurev.ph.54.030192.001303 · Cited by 516
Peroxisome proliterator-activated receptors, orphans with ligands and functions
Schoonjans, K., Martin, G. V., Staels, B., & Auwerx, J. H. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00006 · Cited by 488
Deactivation of peroxisome proliferator–activated receptor-α during cardiac hypertrophic growth
Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9056 · Cited by 466
Induction of Cardiac Fibrosis by Transforming Growth Factor-β1
Lijnen, P. J., Petrov, V. V., & Fagard, R. H. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3032 · Cited by 464
Brandt, J. M., Djouadi, F., & Kelly, D. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.23786 · Cited by 458
Nuclear factor kappa-B and the heart
Valen, G., Yan, Z.-Q., & Hansson, G. K. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01377-8 · Cited by 448
Diep, Q. N., Mabrouk, M. E., Cohn, J. S., Endemann, D., Amiri, F., Virdis, A., Neves, M. F., & Schiffrin, E. L. (2002) · Circulation · doi:10.1161/01.cir.0000016049.86468.23 · Cited by 343
Self-citationCampbell, F., Kozak, R., Wagner, A. M., Altarejos, J. Y., Dyck, J. R. B., Belke, D. D., Severson, D. L., Kelly, D. P., & Lopaschuk, G. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106054200 · Cited by 265
Angiotensin II Induces Cardiac Phenotypic Modulation and Remodeling In Vivo in Rats
Kim, S., Ohta, K., Hamaguchi, A., Yukimura, T., Miura, K., & Iwao, H. (1995) · Hypertension · doi:10.1161/01.hyp.25.6.1252 · Cited by 246
Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat.
Crawford, D. C., Chobanian, A. V., & Brecher, P. I. (1994) · Circulation Research · doi:10.1161/01.res.74.4.727 · Cited by 229
Characterization of angiotensin II receptor subtypes in rat heart.
Sechi, L. A., Griffin, C. A., Grady, E. F., Kalinyak, J. E., & Schambelan, M. (1992) · Circulation Research · doi:10.1161/01.res.71.6.1482 · Cited by 229
Wu, L., Iwai, M., Hironori Nakagami, A., Li, Z., Chen, R., Suzuki, J., Akishita, M., Marc De Gasparo, B., & Horiuchi, M. (2001) · Circulation · doi:10.1161/hc4601.099404 · Cited by 217
Ruiz‐Ortega, M., Lorenzo, Ó., Rupérez, M., Blanco, J., & Egido, J. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64130-2 · Cited by 176
Myocyte death in heart failure
Anversa, P., Kajstura, J., & Olivetti, G. (1996) · Current Opinion in Cardiology · doi:10.1097/00001573-199605000-00004 · Cited by 123
Cardiac aldosterone production and ventricular remodeling
Delcayre, C., Silvestre, J., Garnier, A., Oubénaı̈ssa, A., Cailmail, S., Tatara, E., Bernard Swynghedauw, A., & Robert, V. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00973.x · Cited by 123
Effects of Lipid-Lowering Agents in the Dahl Salt-Sensitive Rat
Wilson, T. W., Alonso‐Galicia, M., & Roman, R. J. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.225 · Cited by 108
Xu, X., Otsuki, M., Saito, H., Sumitani, S., Yamamoto, H., Asanuma, N., Kouhara, H., & Kasayama, S. (2001) · Endocrinology · doi:10.1210/endo.142.8.8340 · Cited by 82
Hypertrophic growth of cultured neonatal rat heart cells mediated by type 1 angiotensin II receptor
宮田, 節., & Haneda, T. (1994) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1994.266.6.h2443 · Cited by 74
Effect of AT1 receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension
Diep, Q. N., Mabrouk, M. E., Yue, P., & Schiffrin, E. L. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00984.2001 · Cited by 68
Self-citationAngiotensin II Increases Left Ventricular Mass Without Affecting Myosin Isoform mRNAs
Sušić, D., Núñez, E., Frohlich, E. D., & Prakash, O. (1996) · Hypertension · doi:10.1161/01.hyp.28.2.265 · Cited by 57
Vascular angiotensin II receptors in renal and DOCA-salt hypertensive rats.
Schiffrin, E. L., Thomé, F. S., & Genest, J. J. (1983) · Hypertension · doi:10.1161/01.hyp.5.6_pt_3.v16 · Cited by 49
Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and disease
Lorell, B. H. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00258-1 · Cited by 48
Kiarash, A., Pagano, P. J., Tayeh, M. A., Rhaleb, N., & Carretero, O. A. (2001) · Hypertension · doi:10.1161/01.hyp.37.1.58 · Cited by 34
Cited by
Sorted by citations
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 652
Xiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 557
Savoia, C., & Schiffrin, E. L. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mnh.0000203189.57513.76 · Cited by 287
Schiffrin, E. L., & Touyz, R. M. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00262.2004 · Cited by 255
Involvement of PPAR nuclear receptors in tissue injury and wound repair
Michalik, L. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27958 · Cited by 243
Metadata
- Authors
- Diep, Q.
- Affiliations
- Montreal Clinical Research Institute (CA)
- Corresponding author
- Diep, Q
- Venue
- Journal of Molecular and Cellular Cardiology
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 36
- Issue
- 2
- Pages
- 295-304
- ISSN
- 0022-2828 (ISSN-L)
- OpenAlex
- W2081813895
- Cited by
- 165
- References
- 34
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 7 · 2014: 6 · 2013: 7 · 2012: 7
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Molecular and Cellular Cardiology (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (acceptedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- fenofibrate, PPARα, angiotensin II, myocarditis, myocardial fibrosis, hypertension, NF-κB, adhesion molecules, TGF-β1, collagen deposition, macrophage infiltration, hyperlipidemia, cardioprotection
- MeSH terms
- Angiotensin II, Animals, Blood Pressure, Collagen, Electrocardiography, Fibrosis, Heart, Hypertension, Inflammation, Infusions, Intravenous, Myocardium, Fenofibrate, Transcription Factors, Transforming Growth Factor beta, NF-kappa B, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear, Intercellular Adhesion Molecule-1, Rats, Transforming Growth Factor beta1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
